Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1
Type 1 Diabetes
About this trial
This is an interventional treatment trial for Type 1 Diabetes
Eligibility Criteria
Inclusion Criteria: 1: Type 1 diabetes for at least 1 year. 2. Age 18 - 70 years. 3. Last known HbA1c <86 mmol/mol. 4. Treated with continuous subcutaneous insulin infusion (CSII) by an insulin pump or multiple daily insulin injections (MDII). Exclusion Criteria: Pregnant women or women trying to conceive. Any chronic disease, including psychiatric illness, judged incompatible with participation in the study. Unfit for participation for any reason judged by the investigators. Known hypersensitivity to glucagon or any of the excipients of the drug formulation. Known phaeochromocytoma. -
Sites / Locations
- Department of Endocrinology, St. Olavs HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Glucagon
Control
Micro dose of glucagon is aded at the insulin injection site
Insulin injected without any glucagon